In contrast, CEACAM5 expression is high in patients with lung adenocarcinoma [41], gastric cancer [42], and colorectal cancer [11, 43] and correlated with poor clinical outcomes and overall survival [44, 45]. Here, CEACAM5 is linked to colorectal cancer.